Los Angeles Capital Management LLC cut its stake in Harpoon Therapeutics, Inc. (NASDAQ:HARP) by 8.1% in the third quarter, HoldingsChannel reports. The firm owned 55,476 shares of the company’s stock after selling 4,860 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Harpoon Therapeutics were worth $438,000 as of its most recent SEC filing.
A number of other large investors also recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its holdings in Harpoon Therapeutics by 2.7% in the second quarter. BlackRock Inc. now owns 1,713,296 shares of the company’s stock valued at $23,765,000 after purchasing an additional 45,745 shares during the period. State Street Corp lifted its holdings in Harpoon Therapeutics by 549.0% during the 2nd quarter. State Street Corp now owns 1,328,368 shares of the company’s stock worth $18,424,000 after buying an additional 1,123,701 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Harpoon Therapeutics by 5.7% during the 2nd quarter. Vanguard Group Inc. now owns 1,255,845 shares of the company’s stock worth $17,419,000 after buying an additional 67,719 shares during the last quarter. Franklin Resources Inc. lifted its holdings in Harpoon Therapeutics by 5.9% during the 2nd quarter. Franklin Resources Inc. now owns 1,137,505 shares of the company’s stock worth $15,777,000 after buying an additional 62,965 shares during the last quarter. Finally, Logos Global Management LP lifted its holdings in Harpoon Therapeutics by 166.7% during the 2nd quarter. Logos Global Management LP now owns 800,000 shares of the company’s stock worth $11,096,000 after buying an additional 500,000 shares during the last quarter. Hedge funds and other institutional investors own 84.40% of the company’s stock.
A number of analysts have issued reports on HARP shares. SVB Leerink reaffirmed a “buy” rating on shares of Harpoon Therapeutics in a report on Thursday, December 16th. Zacks Investment Research raised Harpoon Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 price target for the company in a report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Harpoon Therapeutics in a report on Monday, October 18th. Finally, Citigroup reduced their target price on Harpoon Therapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, November 17th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $24.03.
Harpoon Therapeutics (NASDAQ:HARP) last posted its earnings results on Wednesday, November 10th. The company reported ($0.51) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.01. Harpoon Therapeutics had a negative return on equity of 69.97% and a negative net margin of 397.64%. The business had revenue of $4.48 million during the quarter, compared to the consensus estimate of $6.38 million. Sell-side analysts forecast that Harpoon Therapeutics, Inc. will post -1.58 earnings per share for the current year.
Harpoon Therapeutics Profile
Harpoon Therapeutics, Inc is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies.
Read More: How analysts view the yield curve
Want to see what other hedge funds are holding HARP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harpoon Therapeutics, Inc. (NASDAQ:HARP).
Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.